Natixis Advisors LLC lowered its stake in Teleflex Incorporated (NYSE:TFX - Free Report) by 37.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,178 shares of the medical technology company's stock after selling 7,738 shares during the period. Natixis Advisors LLC's holdings in Teleflex were worth $2,345,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in TFX. Avior Wealth Management LLC boosted its holdings in shares of Teleflex by 190.6% in the 3rd quarter. Avior Wealth Management LLC now owns 154 shares of the medical technology company's stock valued at $38,000 after acquiring an additional 101 shares during the last quarter. True Wealth Design LLC lifted its position in Teleflex by 16,600.0% during the third quarter. True Wealth Design LLC now owns 167 shares of the medical technology company's stock valued at $41,000 after purchasing an additional 166 shares during the period. IFP Advisors Inc boosted its holdings in Teleflex by 238.5% in the fourth quarter. IFP Advisors Inc now owns 308 shares of the medical technology company's stock valued at $55,000 after purchasing an additional 217 shares during the last quarter. Banque Cantonale Vaudoise grew its position in Teleflex by 184.8% during the 3rd quarter. Banque Cantonale Vaudoise now owns 225 shares of the medical technology company's stock worth $56,000 after purchasing an additional 146 shares during the period. Finally, Exchange Traded Concepts LLC raised its stake in shares of Teleflex by 38.2% during the 4th quarter. Exchange Traded Concepts LLC now owns 340 shares of the medical technology company's stock valued at $61,000 after buying an additional 94 shares during the last quarter. 95.62% of the stock is currently owned by institutional investors and hedge funds.
Teleflex Price Performance
Shares of NYSE TFX traded down $0.89 during trading on Thursday, hitting $139.34. The company had a trading volume of 838,993 shares, compared to its average volume of 554,451. The firm has a market capitalization of $6.46 billion, a price-to-earnings ratio of 27.70, a price-to-earnings-growth ratio of 1.73 and a beta of 1.21. The stock has a fifty day simple moving average of $160.91 and a two-hundred day simple moving average of $191.86. The company has a quick ratio of 1.39, a current ratio of 2.42 and a debt-to-equity ratio of 0.37. Teleflex Incorporated has a fifty-two week low of $128.55 and a fifty-two week high of $249.91.
Teleflex (NYSE:TFX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical technology company reported $3.89 EPS for the quarter, topping the consensus estimate of $3.86 by $0.03. The company had revenue of $795.40 million during the quarter, compared to analyst estimates of $813.24 million. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. On average, research analysts expect that Teleflex Incorporated will post 13.98 earnings per share for the current year.
Teleflex Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Monday, March 17th. Shareholders of record on Friday, March 7th were paid a dividend of $0.34 per share. The ex-dividend date of this dividend was Friday, March 7th. This represents a $1.36 annualized dividend and a yield of 0.98%. Teleflex's dividend payout ratio (DPR) is presently 95.77%.
Analyst Ratings Changes
A number of analysts have recently commented on TFX shares. Piper Sandler restated a "neutral" rating and issued a $140.00 target price (down previously from $255.00) on shares of Teleflex in a research note on Friday, February 28th. Raymond James cut shares of Teleflex from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Truist Financial cut their target price on shares of Teleflex from $200.00 to $149.00 and set a "hold" rating for the company in a report on Monday, March 3rd. Bank of America downgraded shares of Teleflex from a "neutral" rating to an "underperform" rating and lowered their price target for the stock from $235.00 to $140.00 in a report on Tuesday, March 4th. Finally, StockNews.com cut shares of Teleflex from a "buy" rating to a "hold" rating in a report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat, Teleflex currently has a consensus rating of "Hold" and an average price target of $182.63.
Read Our Latest Stock Report on TFX
About Teleflex
(
Free Report)
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.
Featured Articles
Before you consider Teleflex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teleflex wasn't on the list.
While Teleflex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
